JP2023516004A5 - - Google Patents
Info
- Publication number
- JP2023516004A5 JP2023516004A5 JP2022551742A JP2022551742A JP2023516004A5 JP 2023516004 A5 JP2023516004 A5 JP 2023516004A5 JP 2022551742 A JP2022551742 A JP 2022551742A JP 2022551742 A JP2022551742 A JP 2022551742A JP 2023516004 A5 JP2023516004 A5 JP 2023516004A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020077148 | 2020-02-28 | ||
| CNPCT/CN2020/077148 | 2020-02-28 | ||
| PCT/CN2021/078051 WO2021170068A1 (en) | 2020-02-28 | 2021-02-26 | Anti-cd137 constructs, multispecific antibody and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023516004A JP2023516004A (ja) | 2023-04-17 |
| JP2023516004A5 true JP2023516004A5 (enExample) | 2024-02-27 |
| JP7702961B2 JP7702961B2 (ja) | 2025-07-04 |
| JP7702961B6 JP7702961B6 (ja) | 2025-07-17 |
Family
ID=77489868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551742A Active JP7702961B6 (ja) | 2020-02-28 | 2021-02-26 | 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230067770A1 (enExample) |
| EP (1) | EP4110827A4 (enExample) |
| JP (1) | JP7702961B6 (enExample) |
| KR (1) | KR20220148228A (enExample) |
| CN (1) | CN115190889A (enExample) |
| AU (1) | AU2021228077A1 (enExample) |
| CA (1) | CA3169943A1 (enExample) |
| WO (1) | WO2021170068A1 (enExample) |
| ZA (1) | ZA202210626B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022001027A (es) * | 2019-07-26 | 2022-04-18 | Abl Bio Inc | Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. |
| AU2022260298A1 (en) * | 2021-04-23 | 2023-11-02 | Shanghai Henlius Biotech, Inc. | Anti-gpc3 antibodies, multispecific antibodies and methods of use |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| CN122180707A (zh) * | 2023-11-06 | 2026-06-09 | 珠海烁星生物医药科技有限公司 | 多特异性癌症靶向抗体 |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026037257A1 (en) * | 2024-08-12 | 2026-02-19 | Shanghai Henlius Biotech, Inc. | Anti-egfr/met multispecific antibodies and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| NZ729044A (en) * | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| EP3613433B1 (en) * | 2014-05-30 | 2022-01-05 | Shanghai Henlius Biotech, Inc. | Anti-epidermal growth factor receptor (egfr) antibodies |
| PE20181349A1 (es) * | 2015-10-07 | 2018-08-22 | Hoffmann La Roche | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador |
| BR112018071612A2 (pt) | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| EP3497120A1 (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| EP3470428A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting cd137 and methods of use thereof |
| CN110818795B (zh) * | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
-
2021
- 2021-02-26 CN CN202180015561.7A patent/CN115190889A/zh active Pending
- 2021-02-26 CA CA3169943A patent/CA3169943A1/en active Pending
- 2021-02-26 WO PCT/CN2021/078051 patent/WO2021170068A1/en not_active Ceased
- 2021-02-26 KR KR1020227033169A patent/KR20220148228A/ko active Pending
- 2021-02-26 AU AU2021228077A patent/AU2021228077A1/en active Pending
- 2021-02-26 JP JP2022551742A patent/JP7702961B6/ja active Active
- 2021-02-26 EP EP21761044.3A patent/EP4110827A4/en active Pending
-
2022
- 2022-08-26 US US17/822,737 patent/US20230067770A1/en active Pending
- 2022-09-26 ZA ZA2022/10626A patent/ZA202210626B/en unknown